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Incidence and epidemiology
The incidence of hepatocellular carcinoma (HCC) has been rising worldwide over the last 20 years and is expected to increase until 2030 in some countries including the United States, while in other countries, such as Japan, the incidence has started to decline [1] [2] [3] . In 2012, liver cancer represented the fifth most common cancer in men (554 000 new cases) and the ninth in women (228 000 new cases) and the second most common cause of cancer-related death (746 000 estimated deaths), worldwide [3] . The incidence varies from 3/100 000 in Western countries, to 78.1/100 000 in Mongolia, with the highest incidence in Africa and Asia, mapping the geographical distribution of viral hepatitis B (HBV) and hepatitis C (HCV), the most important causes of chronic liver disease and HCC [4] . In Europe, the estimated incidence rate was 10.0 in men and 3,3 in women per 100 000, respectively, in 2012 while the estimated mortality rate was 9.1 and 3.3 per 100 000 in men and women, respectively [3] . The incidence of HCC shows a strong male preponderance and increases progressively with advancing age in all populations. The association of chronic liver disease and HCC represents the basis for preventive strategies, including universal vaccination at birth against HBV [I, A] [5] and early antiviral treatment of viral HBC and HCV [III, A] [6] [7] [8] .
The prevalence of obesity and type 2 diabetes has greatly increased in the past decades leading to a rising incidence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), which can lead to fibrosis and cirrhosis and, eventually, HCC [9] . HCC related to NAFLD/NASH is probably underestimated [10] and is expected rise in the future, possibly overtaking the other aetiologies in some areas of the world [11] . A significant proportion of patients with NAFLD/NASHassociated HCC do not have histological evidence of cirrhosis [12] .
The control of other risk factors for chronic liver disease and cancer is more difficult to implement, such as cutting down on the consumption of alcohol and programmes aiming at a healthier lifestyle in the light of the obesity pandemic [13, 14] . In Africa, reduction of exposure to aflatoxin B1, especially in HBV-infected individuals, may lower the risk of HCC. HCC may evolve from subclasses of adenomas; in < 10% of cases HCC occurs in an otherwise normal liver.
Surveillance
Surveillance of HCC involves the repeated application of screening tools in patients at risk for HCC and aims for the reduction in mortality of this patient population. The success of surveillance is influenced by the incidence of HCC in the target population, the availability and acceptance of efficient diagnostic tests and the availability of effective treatment. Cost effectiveness studies suggest surveillance of HCC is warranted in all cirrhotic patients irrespective of its aetiology [15] , as long as liver function and comorbidities allow curative or palliative treatments [III, A]. Surveillance of non-cirrhotic, hepatitis-infected patients should also be considered in chronic HBV carriers or HCV-infected patients with bridging fibrosis (F3) [III, A], which are at higher risk than the general population. Specifically in Asian patients, serum HBV-DNA above 10,000 copies/mL was associated with a higher annual risk (above 0.2%/year) compared to patients with a lower viral load [16] . Patients with HCV infection and advanced fibrosis remain at increased risk for HCC even after achieving sustained virological response following antiviral treatment [III, A] [8] and, thus, should remain in a surveillance programme. Japanese cohort studies have shown that surveillance by abdominal ultrasound resulted in an average size of the detected tumours of 1.6 ± 0.6 cm, with < 2% of the cases exceeding 3 cm [17] . In the Western world and in less experienced centres, sensitivity of finding early-stage HCC by ultrasound is considerably less effective [18] .
There are no data to support the use of contrast-enhanced computed tomography (CECT) or magnetic resonance imaging (CEMRI) for surveillance. Adding the determination of serum alpha foetoprotein (AFP) to ultrasound (US) can lead to a 6% gain in the early HCC detection rate, but at the price of false-positive results and of a worse cost/effectiveness ratio [19] . A randomised controlled trial (RCT) of Chinese patients with chronic HBV infection compared surveillance (US and serum AFP measurements every 6 months) versus no surveillance [20] . Despite low compliance with the surveillance program (55%), HCC-related mortality was reduced by 37% in the surveillance arm. Considering the most appropriate surveillance interval, a randomised study comparing a 3-versus 6-month schedule failed to detect any differences [21] .
Surveillance of patients at risk for HCC should be carried out by abdominal US every 6 months with or without AFP [II, A].
Diagnosis and pathology/molecular biology
The diagnosis of HCC is based on histological analysis and/or contrast-enhanced imaging findings [III, A]. The diagnostic work-up of a patient with an HCC-suspicious nodule is given in Table 1 .
Diagnosis by imaging
In patients with liver cirrhosis and specific imaging criteria, a formal pathological proof is not mandatory for diagnosis and the clinician can rely on the contrast-enhanced imaging criteria for lesion characterisation [22] [23] [24] . These criteria require a multi-phasic CECT or CEMRI. The diagnosis can be established if the typical vascular hallmarks of HCC (hypervascularity in the arterial phase with washout in the portal venous or delayed phase) are identified in a nodule of > 1 cm diameter using one of these two modalities [ 
Diagnosis by pathology
Pathological diagnosis of HCC is based on a biopsy or a surgical specimen of the tumour. Concomitant analysis of the non-tumour liver may be useful in order to define its status and potential causative diseases. Assessment of resection and explant specimen follows the valid TNM (tumour, node, metastasis) classification including resection margin evaluation. Usually tumour grade is provided, but currently no uniform grading scheme is used worldwide and data on the independent prognostic value are inconclusive. has been consented as a diagnostic panel (2/3 markers positivity has 70% sensitivity and 100% specificity for HCC) and the use of further markers seems to increase the sensitivity [IV, B] [38] . Moreover, histological subtypes of HCC have been defined (e.g. fibrolamellar, chromophobe, macrotrabecular massive) which specifically correlate with clinical and molecular features [39, 40] , which may have future clinical impact.
It is now well accepted that the potential risks of tumour biopsy, bleeding and needle track seeding, are infrequent, manageable and do not affect the course of the disease or overall survival (OS) and, therefore, should not be seen as a reason to abstain from diagnostic liver biopsy. In a comprehensive meta-analysis, the risk of tumour seeding after liver biopsy was reported to be 2.7%, with a median time interval between biopsy and seeding of 17 months [41] , but even lower rates are expected in experienced centres. It was reported that needle track seeding can be treated well (e.g. by excision or radiation) and did not affect outcome of oncological treatment [42] and OS [41] . In a meta-analysis of the bleeding risk, mild bleeding complications ranged around 3%-4%, while severe bleeding complications, requiring transfusions, were reported in 0.5% of the cases [43] .
Staging and risk assessment
Staging of HCC is important to determine outcome and planning of optimal therapy and includes assessment of tumour extent, AFP level, liver function, portal pressure and clinical performance status (PS) ( include contrast-enhanced MRI or helical CT. CT of the chest, abdomen and pelvis is recommended to rule out extrahepatic spread. There is no justification for routine preoperative bone scintigraphy to detect asymptomatic skeletal metastases in patients with resectable HCC [44] and there are no data in the context of advanced HCC. There is no demonstrated clinical benefit of performing FDG-PET scan as a staging modality, despite some evidence that there is a correlation of higher FDG uptake with poor differentiation, tumour size, serum AFP levels and microvascular invasion [IV, D] [45, 46] .
Liver function is classically assessed by the Child-Pugh scoring system (serum bilirubin, serum albumin, ascites, prothrombin time and hepatic encephalopathy) [III, A]. Within the Child-Pugh A group, measurement of the albumin-bilirubin (ALBI) score (a model incorporating serum albumin and bilirubin levels alone) is able to split that group into best prognosis (ALBI 1) and lesser prognosis (ALBI 2), with median survivals of 26 months versus 14 months, respectively [IV, B] [47] . A platelet count > 150 × 10 9 cells/L and a non-invasive liver stiffness measurement < 20 kPa excludes clinically significant portal hypertension (Baveno VI criteria) [48] . Otherwise, the finding of oesophageal varices and/or splenomegaly with blood platelet counts of 100 × 10 9 cells/L suggests clinically important portal hypertension, which can also be measured invasively by the transjugular route (hepatic-venous pressure gradient > 10 mmHg) [III, A].
Several staging systems-incorporating some or all of the above-mentioned itemshave been developed, including TNM, Okuda, Cancer of the Liver Italian Program (CLIP), Japanese Integrated Staging (JIS) Score and the Barcelona Clinic Liver Cancer (BCLC) system. Every system has advantages and drawbacks. The recently released 8th edition of the TNM system (Table 3 ) contains changes to the T classifications compared with the previous staging system [49] . The staging system includes microvascular invasion, that can only be assessed on pathology and is therefore less useful in clinical practice prior to treatment decision. Moreover, a recent validation study pointed to potential problems of heterogeneity in the T2 category and the lack of vascular invasion as a prognostic factor in the T3 group [50] . TNM classification provides a means of standardising histopathological reports in patients treated by resection or transplantation. The BCLC staging system was developed on the basis of the results of RCTs and cohort studies and links tumour stage, liver function, cancer-related symptoms and PS to an evidence-based treatment algorithm ( Table 4 ). The system identifies those patients with early HCC who may benefit from ablative treatment (stage 0 and A), those at intermediate (stage B) or advanced stage (stage C) who may benefit from intraarterial or systemic treatments and those with a very poor life expectancy (stage D).
Survival without therapy is > 5 years for stage 0 and A, > 2.5 years for stage B, > 1
year for stage C and around 3 months for stage D [51] . Treatment assignment of the different stages will be discussed below. The aetiology of co-existent liver disease has not been identified as an independent prognostic factor. Nevertheless, finding a treatable underlying co-existent liver disease may be very relevant: e.g. antiviral treatment in case of HBV, corticosteroid treatment in autoimmune hepatitis or stopping alcohol intake may result in a marked improvement in liver function and improving prognosis.
Liver decompensation (including jaundice, variceal hemorrhage, ascites or encephalopathy) should be considered a contraindication for any locoregional therapy that may induce subclinical liver damage such as resection, percutaneous ablation or transarterial therapies. The benefit of systemic therapies has not been established in patients with liver decompensation.
Management of early and intermediate HCC
Liver resection (LR), orthotopic liver transplantation (OLT) and local destruction methods [radiofrequency ablation (RFA) or microwave ablation (MWA)] comprise potentially curative treatment modalities for patients with HCC (see Figure 1 ). Selecting the appropriate treatment for the individual patient remains difficult and there are no randomised phase III trials comparing the efficacy of these three approaches; all evidence is based on cure rates in patient series.
The predominant arterial vascularisation of HCC resulted in the application of intraarterial administration of chemotherapy (e.g. doxorubicin, cisplatin), embolising material (e.g. coils, gelatin sponge particles) or radioactive particles. These therapies are generally regarded as palliative treatment options but may provide complete tumour destruction in well-selected candidates.
Liver resection
Single tumours in patients with well-preserved liver function is the mainstay indication In comparison to open LR, laparoscopic LR results in reduced intraoperative blood loss, faster postoperative recovery and does not impair oncological outcome [54] . LR in cirrhosis should preferably be carried out as laparoscopic resection [IV, A]. Currently there is no high-level evidence to recommend surgical resection in cirrhotic HCC patients with advanced tumour burden and macrovascular invasion.
After LR, tumour recurrence can be observed in 50% to 70% of cases within 5 years following surgery, which constitutes either intrahepatic metastases (often within 2 years following surgery) or a new HCC in the remaining cirrhotic liver (occurring more often beyond 2 years). Even though the vast majority of HCC recurrences occur within the liver as a result of subclinical micro-metastases and vascular invasion from the primary tumour, the extent of surgical resection [anatomical resection (AR) versus nonanatomical wedge resection (NAR)] is still a subject of ongoing debate. Theoretically, the systematic removal of the hepatic segment through an AR is considered to be more effective in terms of tumor clearance and eradication of micro-metastases [55] . This however is rarely possible in cirrhotic HCC patients for which tissue-sparing NAR is the procedure of choice to reduce the risk of postoperative liver failure [56] . While some groups report superiority of AR, overall conflicting results are reported, and no clear recommendation may be given due to a lack of currently available high-level clinical evidence [57, 58] . have failed to improve recurrence-free survival in a recently published phase III study [65] . Similarly, sorafenib did not improve median recurrence-free survival of HCC patients after LR or local ablation [66] Thermal tumour ablation Thermal ablation by means RFA or MWA may be recommended as first-line treatment in very early-stage disease (BCLC 0) [II, A]. In very early-stage disease (tumours < 2 cm diameter), RFA has demonstrated similar outcomes to LR and thus may be recommended as first-line treatment, specifically in light of its lesser invasiveness and morbidity compared with surgery [64] . In patients with early-stage HCC (up to three lesions up to 3 cm), RFA has been adopted as an alternative first-line option irrespective of liver function after demonstrating survival benefit similar to surgery in RCTs and meta-analyses [64, [67] [68] [69] [70] . To date, MWA has not been adequately tested in comparison to RFA and the potential advantage for tumours between 3 to 5 cm or the reduced impact of the cooling effect of adjacent large vessels remains unknown.
Orthotopic liver transplantation
Both methods have limitations in exophytic tumours as well as those close to the gallbladder, liver hilum or with neighbouring intestine, which may be overcome with laparoscopic surgery [71] . Chemical tumour ablation (e.g. by ethanol injection) plays no role, since thermal ablation has proven better disease control and outcomes [72] .
In very small lesions, superiority of thermal ablation is minimal [73] .
High conformal, high dose rate radioablation (stereotactic body radiotherapy; high dose rate brachytherapy) High conformal high dose rate (HDR) radioablation and stereotactic body radiotherapy (SBRT) may be considered as alternatives for the ablation of tumours with a high risk of local failure after thermal ablation due to location [III, C]. High conformal irradiation techniques with hypofractionated (SBRT) or single fraction dose regimens (HDR brachytherapy) have evolved as alternatives to thermal ablation in recent years. In contrast to classic fractionated irradiation schemes, high conformal HDR irradiation techniques such as SBRT or CT-guided HDR brachytherapy have proven efficacy with tumour control rates > 90% after 12 months in up to 5 cm (SBRT) or up to 12 cm tumour diameter (HDR brachytherapy) in single-centre studies [74] [75] [76] [77] . However, a recent comparative trial has demonstrated better survival when applying RFA than SBRT in small tumours ≤ 3 cm [78] . In contrast to thermal ablation, high conformal HDR radioablation is not limited by adjacency to large vessels, exophytic growth or central location. Both SBRT and HDR brachytherapy have demonstrated excellent safety profiles [79, 80] . External beam radiotherapy can be used to control pain in patients with bone metastases [III, B] . Any ablation recommendation should be proposed by the local multidisciplinary meeting (MDM) based on liver function, tumour size, tumour location and the medical expertise provided by the given treatment centre.
Transarterial therapies
The almost exclusive arterial vascularisation of HCC resulted in the application of intraarterial infusion of chemotherapy alone (doxorubicin, cisplatin, mytomicin C or combinations), mixed with the contrast agent lipiodol (ethiodised oil) that is selectively retained by HCC nodules, embolising material (e.g. coils, gelatin sponge pieces or polyvinyl alcohol-calibrated particles) or tiny radioactive particles containing yttrium-90
Absolute contraindications for transarterial therapies are decompensated cirrhosis, extensive tumour burden, reduced portal vein flow, renal failure or any technical contraindication to transarterial therapy. Important relative contraindications include bile duct occlusion or incompetent papilla, reduced PS, impaired liver function (Child-Pugh B), high-risk oesophageal varices, portal vein thrombosis of any kind for TACE or involving the main trunk for selective internal radiotherapy (SIRT) [81] .
Transarterial chemoembolisation
Overall, the efficacy of TACE has been explored in seven randomised trials compared with best supportive care [82] . Only two studies reported a survival benefit for the treatment arm [83, 84] . The benefit of TACE in prolonging OS was demonstrated in selected asymptomatic patients with maintained liver function that belong to the BCLC-A stage to early intermediate BCLC-B stage, who had a small tumour burden but were not amenable to surgery or local ablation [I, A]. Median OS of 30-45 months can be expected in this population [85] [86] [87] . Shorter median survival of < 20 months has been reported in real life cohorts when patients with no proven benefit are treated including those in Child-Pugh B stage, with portal vein invasion, large tumour burden or deteriorating liver function under TACE [88] [89] [90] [91] . Several scores have been developed to identify patients that benefit from TACE from retrospective cohort studies. Currently, only the hepatoma arterial-embolisation prognostic (HAP) score has been validated in a prospective trial and in multiple large international data set [92, 93] . The HAP score is able to define four distinct prognostic groups with respect to OS and could be used as a stratification factor for TACE trials in future [88] . Outside clinical trials, the use of therapeutic algorithms based on prognostic scores of unknown predictive values is currently not recommended for the selection of candidates to initial and repeated TACE 
Selective internal radiotherapy
SIRT is based on the injection of microspheres loaded with the pure beta emitter 90 Y into the hepatic arterial circulation and has no or minimal ischaemic effect. SIRT with 90 Y glass or resin microbeads produces tumour responses and high disease control rates with a safe profile in phase II studies and registries [102] . In the phase III studies, SIRT was associated with higher response rates, delayed tumour progression in the liver and fewer adverse events (AEs) compared with sorafenib. The observed delay in tumour progression was also observed in retrospective cohort studies with survival rates comparable to those reported for TACE and sorafenib [106] [107] [108] . Thus, in exceptional circumstances, for patients with liverconfined disease and preserved liver function in whom neither TACE nor systemic therapy are possible, SIRT may be considered. Additionally, SIRT may be considered instead of TACE for the treatment of small tumours in patients waiting for liver transplantation in an attempt to avoid drop-out from the list due to tumour progression [106] .
Management of advanced disease
During the past 40 years, numerous RCTs testing treatments for advanced HCC have been published [109] . Sorafenib showed a survival benefit and it was established as the sole systemic treatment for patients with advanced HCC or those progressing from locoregional therapies. More recently, five additional drugs have shown positive clinical results in first-and second-line settings (see Figure 1 ).
Systemic therapies for advanced HCC

Chemotherapy
Chemotherapy has not been shown to improve survival in randomised trials and is not recommended as a standard of care [II, C].
To date, four trials have been reported for which the experimental arms were: PIAF (cisplatin/interferon/doxorubicin/fluorouracil), the tubulin binding agent T138067, nolatrexed and FOLFOX (leucovorin/fluorouracil/oxaliplatin) [110] [111] [112] . None improved survival compared with doxorubicin, although response rates were higher with FOLFOX (8.2% versus 2.7%, P=0.0233) and a small benefit in median survival was also seen on long-term follow up (6.4 months versus 5.0 months, P=0.0425). One trial has compared sorafenib with the combination of sorafenib and doxorubicin but did not demonstrate improved survival with combination therapy [113] . In summary, the clinical benefit of chemotherapy in the management of HCC has not been established.
Targeted therapies
First-line therapies
Sorafenib is the standard of care for patients with advanced HCC and those not eligible 7.9 months to 10.7 months) [114] . The target population of this trial was mostly patients with advanced HCC (80%, including 35% with macrovascular invasion and 50% with extrahepatic spread). The results of the SHARP trial were subsequently confirmed in the Asia-Pacific phase III trial [115] and in 10 subsequent trials with a mOS in the range of 10-12 months. Objective responses are uncommon; 2% by Response Evaluation Criteria in Solid Tumours (RECIST) and ~10% by modified RECIST (mRECIST) [116] .
A recent meta-analysis of individual data of two RCTs testing sorafenib has shown that, although of benefit to all patients across the board, it provides better outcomes in patients with HCV-related HCC and those with liver-only disease [117] . No predictive biomarkers of responsiveness to sorafenib have been identified.
The recommended daily dose of sorafenib is 800 mg. Median treatment duration is estimated to be of 5-6 months, but early prevention of toxicities can enhance tolerability. Treatment is associated with manageable AEs, such as diarrhoea, handfoot skin reactions, fatigue and hypertension. Around 15% of patients are intolerant to sorafenib, and thus treatment needs to be withdrawn, while another 35% of patients require dose reduction. Treatment-related liver failure or life-threatening complications are marginal. Considering the restrictive indication of sorafenib in terms of liver failure (mostly Child-Pugh A class), it has been estimated that only half of patients at advanced stages can be suitable for this treatment. Clinically symptomatic vascular disease-either coronary or peripheral-is considered a formal contraindication.
Lenvatinib
Several phase III trials have been conducted to challenge sorafenib in front line (testing sunitinib, brivanib, erlotinib, linifanib or doxorubicin), but lenvatinib has only recently shown non-inferior clinical efficacy [118] . Lenvatinib is an oral multikinase inhibitor that 
Second-line therapies:
Regorafenib is the standard of care for patients with advanced HCC who have 
Regorafenib
Recently, a phase III study comparing regorafenib (a multikinase inhibitor targeting similar kinases as sorafenib) with placebo in patients progressing despite sorafenib has reported a benefit in survival (HR: 0.62; p<0.0001, mOS 7.8 to 10.6 months) [119] .
Treatment improved survival in all subgroups of patients. In this trial, 88% of patients were BCLC C and 12% BCLC B, with all of them tolerant to but progressing on sorafenib. Around 30% of patients presented with macrovascular invasion: 70% with extrahepatic spread and 45% with AFP > 400 ng/dL. Response rate was 10%, based upon mRECIST. Treatment was started at 160 mg/day (3 weeks on/1 week off).
Median time on treatment was 3.5 months. AEs led to 51% dose reductions and 10% treatment discontinuation. Approval of regorafenib as a standard of care opens the field for third-line therapies. It should be kept in mind, however, that most patients at BCLC B-C stages not candidates to standard of care therapies (TACE, sorafenib, regorafenib) are generally unsuitable candidates to enter into clinical trials. These patients, along with those at BCLC D stage should receive best supportive/palliative care including management of pain, nutrition and psychological support.
Cabozantinib
Cabozantinib is a MET, VEGFR2, AXL and RET inhibitor approved for thyroid and renal cancer. The CELESTIAL trial, a randomised, global phase III trial, examined cabozantinib versus placebo in patients with advanced HCC who had been previously treated with sorafenib [120] . In contrast to regorafenib, this trial allowed the inclusion of patients that were intolerant to sorafenib and who had progressive disease on one or two systemic therapies. In this trial, 30% of patients presented with macrovascular invasion, 78% with extrahepatic spread and 42% with AFP > 400 ng/dL. Treatment was started at 60 mg/day. Median time on treatment was 3.8 months. OS results favoured cabozantinib compared with placebo (HR 0.76, 95% CI: 0.63-0.92; P=0.0049; mOS 10.2 months versus 8.0 months). Response rate was 4% with cabozantinib based upon RECIST v1.1. The most common grade 3/4 AEs with cabozantinib versus placebo were palmar-plantar erythrodysesthaesia (17% versus 0%), hypertension (16% versus 2%), increased aspartate aminotransferase (12% versus 7%), fatigue (10% versus 4%) and diarrhoea (10% versus 2%) and led to 62% dose reductions and 16% treatment discontinuation.
Ramucirumab
RAM is a human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that inhibits ligand activation of VEGFR2. In the phase III REACH trial mOS in the overall population was not statistically significant, but a meaningful improvement was observed in a patient subgroup with baseline AFP ≥ 400 ng/mL. Based on these data, the REACH-2 phase III trial analysed the efficacy of RAM in patients with elevated baseline AFP following therapy with sorafenib. RAM treatment significantly improved mOS from 7.3 to 8.5 months (HR 0.710; 95% CI: 0.531, 0.949; P=0.0199) and mPFS from 1.6 to 2.8 months (HR 0.452; 95% CI: 0.339, 0.603; P<0.0001) compared to placebo [121] . ORR was 4.6% with RAM versus 1.1% with placebo (P=0.1156) and ORR was 59.9% RAM versus 38.9% with placebo (P=0.0006). The safety profile observed in the REACH-2 study was consistent with what has been previously observed, and the only grade ≥3 AEs occurring at a rate of ≥ 5% in the RAM arm were hypertension (12.2% versus. 5.3%) and hyponatremia (5.6% versus 0%).
Immunotherapies
Immunotherapy with nivolumab and pembrolizumab can be considered in patients who are intolerant to, or have progressed under, approved tyrosine kinase inhibitors, pending approval by the EMA [III, B]. For a definitive recommendation, it is necessary to wait for the results of randomised trials.
To date, the most promising immunotherapeutic approach has been the use of immune 2) and mOS was 12.9 months (95% CI: 9.7 -15.5) [124] .
Ongoing research in personalised therapy for HCC
Molecular profiling is not recommended as standard of practice since it currently has no direct implication for decision making. However, we recommend obtaining tissue in all research studies for exploring biomarkers of response.
There has been increasing interest in stratified trials driven by predictive biomarkers, and a number of earlier phase trials are exploring this strategy in HCC. Investigations into the molecular pathology of HCC have identified recurrent mutations of which the most common are in the TERT promotor, CTNNB1, TP53 and epigenetic regulators including ARID1A and ARID2 [125] . While these pathways provide a challenge for drug development, less common molecular aberrations are tractable and show promise. For example, overexpression of FGF19 is found in up to 20% of HCCs, and several compounds directed against its receptor FGFR4 are in development including BLU-554 and FGF401. Despite the disappointing results of the tivantinib phase III trial [126] , there are ongoing studies enriching for MET pathway activation or MET overexpression with INC280 and MSC2156119J. Activation of the TGFβ1 (transforming growth factor beta 1) pathway is associated with a more aggressive subclass of HCC and is being targeted with galunisertib in combinations with sorafenib and nivolumab although these trials are not currently enriched for pathway activation.
Numerous other targets are being evaluated including AR (androgen receptor), STAT3
(signal transducer and activator of transcription 3) (inhibitor HDACi (histone deacetylase inhibitor) and CDK 4/6 (cyclin-dependent kinase 4/6), but, while personalised therapy holds promise for the future, there is insufficient evidence for molecular stratification at the present time. (Table 5 ) [116] . The mRECIST criteria also include guidelines regarding evaluation of vascular invasion, lymph nodes, effusions and new lesions. In 2011, the first study reported a link between mRECIST, European Association for the Study of Liver (EASL) and OS in patient treated with TACE in contrast to RECIST v1.1, which was subsequently confirmed and validated [127] [128] [129] [130] . In contrast to locoregional therapies, the value of mRECIST in the evaluation of systemic therapy in HCC is not yet established. mRECIST was prospectively evaluated in the BRISK trial and responders had a better OS compared with non-responders [131] ; however, a higher objective response by mRECIST does not correlate with an improved OS in subsequent phase III trials [118] . In addition, the prospective comparison between mRECIST and RECIST in two trials with nintedanib and one trial with regorafenib revealed a very similar outcome with no clear advantage of mRECIST [119, 132] . Overall, mRECIST criteria need further prospective validation but may be used in daily clinical practice to consider not only tumour diameters but also lesion viability in therapy decision making [III, B]. There is limited evidence that OS can be predicted more accurately by mRECIST compared with RECIST v1.1 [IV, B].
Follow-up, long-term implications and survivorship
Response assessment following radioembolisation is challenging and should be carried out by multiple phase MRI or CT at approximately 3-4 months intervals.
Imaging carried out early after radioembolisation may show arterial enhancement (both rim and intratumoural) related to post-treatment inflammatory changes and may be erroneously labelled as infiltrative tumour. These findings usually resolve after 6 months [133] . Prospective radiological-pathological studies have shown that EASL and mRECIST-and not World Health Organization (WHO) or RECIST-may capture responses at 3 months after radioembolisation [134] .
In the context of immunotherapy, response evaluation may also be very challenging as pseudoprogression (transient increase in tumour size and AFP, followed by response) has been described also in HCC [135] . Recent trials with immunotherapies reported response rates of up to 25% by RECIST v1.1, and mRECIST has not been validated in this setting. Serum tumour markers (such as AFP levels) may be helpful particularly in the case of not easily measurable disease but should not be used as the only determinant for treatment decision [IV, B]. Pseudoprogression is incredibly rare but, in the future, immune RECIST (iRECIST) needs to be discussed in this context [136] . Table 6 . Levels of evidence and grades of recommendation have been applied using the system shown in Table 7 . Statements without grading were considered justified standard clinical practice by the experts and the ESMO Faculty.
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BCLC, Barcelona Clinic Liver Cancer; BSC, best supportive care; EMA, European Medicines Agency; HCC, hepatocellular carcinoma; LTX, liver transplantation; SBRT SIRT, selective internal radiotherapy; TACE, transarterial chemoembolisation.
